A Brazilian Ozempic Rival Takes On a $1 Billion Weight-Loss Market

Markets

Key Facts

—The move. Brazil’s Hypera filed to launch Semavy, its own semaglutide pen.

—The rival. It targets the same drug class as Novo Nordisk’s Ozempic.

—The market. Semaglutide moves at least R$5bn ($960m) a year in Brazil.

—The trigger. Semaglutide’s Brazilian patent expired in March 2026.

—The first. Rival EMS already won approval in May for its version, Ozivy.

—The catch. Semavy still awaits final sanitary registration before it can sell.

The race to make Brazil weight-loss drugs cheaper has a new contender, as a big domestic drugmaker files to sell its own version of the blockbuster injections that have reshaped how the world treats obesity and diabetes.

A Brazilian company is going after one of the most lucrative drugs of the decade. Hypera, one of the country’s largest drugmakers, has taken a formal step toward selling its own version of the medicine sold globally as Ozempic.

The product is an injectable pen called Semavy. On June 24 the company filed it with Brazil’s drug-pricing chamber, the step that comes just before final approval to sell.

For a reader far from Brazil, the appeal is simple. A market currently dominated by expensive imported brands is about to face cheaper local competition, and that is a business story as much as a medical one.

Why Brazil weight-loss drugs are such a prize

The numbers explain the rush. By industry estimates, semaglutide, the active ingredient in these pens, moves at least five billion reais a year in Brazil, around nine hundred and sixty million dollars, counting only officially registered products.

The true figure is larger still. That estimate leaves out compounded versions mixed in pharmacies and the pens smuggled in from neighbouring Paraguay, both signs of how fierce the demand has become.

These medicines belong to a class known as GLP-1 drugs. They mimic a natural hormone that controls blood sugar and curbs appetite, which is why they treat both type-two diabetes and obesity.

Two foreign brands have led the way. Ozempic, made by Denmark’s Novo Nordisk, and Mounjaro, from America’s Eli Lilly, are the names Brazilian patients know best, and the most expensive.

What opened the door to local rivals

The opening came from a patent. Semaglutide lost its protection in Brazil in March of this year, freeing domestic firms to make their own versions for the first time.

Hypera is not even first through the gate. A rival Brazilian firm, EMS, won approval in May for its own pen, called Ozivy, which has begun reaching pharmacies this month.

There is a regulatory quirk worth noting. The local versions are not classed as generics but as new medicines, because Brazilian rules do not allow a true generic category for this kind of complex drug.

The original maker is fighting back. Novo Nordisk has partnered with a Brazilian firm, Eurofarma, to sell its own locally produced semaglutide under new brand names for both weight loss and diabetes.

The government has put its thumb on the scale. Last year the health ministry pushed the regulator to fast-track around twenty applications for weight-loss drugs, moving them up the approval queue.

A grey market underlines the demand. Alongside the official brands, Brazilians have turned heavily to pharmacy-compounded copies and pens smuggled from Paraguay, which the regulator is now trying to stamp out.

How the Brazil weight-loss drugs fight plays out

More sellers usually mean lower prices. Analysts expect the arrival of several domestic pens to push down the cost of treatment, widening access for patients who cannot afford the imported brands.

The government is watching closely. Officials hope cheaper local versions might eventually be offered through the public health system, which would turn a private boom into a far larger public market.

Hypera’s pen is aimed first at diabetes. The company plans to launch Semavy for type-two diabetes and later seek approval for weight loss, the faster-growing use.

What it means for investors

For investors, the contest shows how quickly a patent cliff reshapes a market. The high margins that foreign giants enjoyed on these drugs are now exposed to a wave of cheaper local competition.

The prize for the winners could be large. A domestic firm that captures even a slice of a multibillion-real market, and later sells into the public system, stands to gain a durable new revenue stream.

There are real hurdles, too. Semavy still needs its final sanitary registration, and making these complex injectables reliably and at scale is harder than making an ordinary pill.

The wider pattern reaches beyond Brazil. As patents on the world’s hottest drugs expire, emerging-market manufacturers are racing to localise them, a shift that could reshape global pharmaceutical profits.

Brazil weight-loss drugs questions, answered

What did Hypera announce?

It filed its own semaglutide pen, called Semavy, with Brazil’s drug-pricing chamber, a step before final approval to sell. The pen targets the same class of drugs as Ozempic and is aimed first at type-two diabetes.

Why are local versions appearing now?

Semaglutide’s patent expired in Brazil in March 2026, allowing domestic firms to make their own versions. A rival, EMS, already won approval in May for its pen, Ozivy, which is now reaching pharmacies.

How big is the market?

Industry estimates put registered semaglutide sales in Brazil at a minimum of five billion reais a year, about nine hundred and sixty million dollars. The real total is higher once compounded and smuggled products are counted.

The Rio Times · Power Map

See who really holds power in Latin America

Click to open the Power Map →